News
With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.
Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling ...
First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...
4d
Investor's Business Daily on MSNEli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound BeatsEli Lilly stock fell Thursday after the drugmaker cut its full-year profit guidance despite a first-quarter beat.
Emmy Award-winning actor Eric Stonestreet, known for his portrayal of Cameron Tucker on ABC’s hit sitcom Modern Family, has revealed his private health journey with type 2 diabetes and how medication ...
Q, reporting significant increases in revenue and net income for the three months ended March 31, 2025. Revenue surged to $12 ...
Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results